Lung Cancer Clinical Trial

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Summary

This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-squamous non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonucleic acid (DNA), which is a natural substance in every living organism. DNA acts like a blueprint that tells all the cells in your body how to function. The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2). STEMVAC is given with granulocyte-macrophage colony stimulating factor (GM-CSF) which is being used as an adjuvant to help create a stronger immune response. Giving STEMVAC with GM-CSF to patients while on maintenance therapy for non-small cell lung cancer (NSCLC) may help activate certain immune cells to recognize and kill lung cancer cells.

View Full Description

Full Description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive STEMVAC intradermally (ID) and sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.

ARM II: Patients receive sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.

After completion of study treatment, patients are followed up twice yearly for up to 5 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically-confirmed diagnosis of stage IV non-squamous non-small cell lung cancer (NSCLC).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within one month of first vaccine. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
Have completed 4 cycles of carboplatin, pemetrexed and pembrolizumab, without evidence of progressive disease.
Have not received more than 2 cycles of maintenance pembrolizumab and pemetrexed and be a candidate for continuation of this therapy.
At least 1 site of disease that could be biopsied during treatment. This site should not be a site that is used to determine measurable disease for efficacy purposes. Lesions that will be biopsied should not be on a previously irradiated area unless progression has been demonstrated in such lesions.
Patients must be at least 28 days post systemic steroids prior to enrollment, unless this is a steroid administered concurrently with the pemetrexed.
Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment.
Willing to undergo two serial biopsies while on study.
Estimated life expectancy of more than 6 months.
White blood cells (WBC) >= 3000/mm^3 (within 30 days of first vaccination).
Lymphocyte count >= 800/mm^3 (within 30 days of first vaccination).
Platelet count >= 75,000/mm^3 (within 30 days of first vaccination).
Hemoglobin (Hgb) >= 9 g/dl (within 30 days of first vaccination).
Serum creatinine =< 1.2 mg/dl or creatinine clearance > 50 ml/min (within 30 days of first vaccination).
Total bilirubin =< 1.5 mg/dl (within 30 days of first vaccination).
Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) =< 2 times upper limit of normal (ULN) or SGOT =< 5 times upper limit of normal (ULN) in the presence of liver metastasis (within 30 days of first vaccination).
If female of childbearing potential has a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study.
Patients must be at least 18 years of age.

Exclusion Criteria:

Patients with any of the following cardiac conditions:

Symptomatic restrictive cardiomyopathy
Unstable angina within 4 months prior to enrollment
New York Heart Association functional class III-IV heart failure on active treatment
Symptomatic pericardial effusion
Patients with central nervous system (CNS) metastasis that have not been treated. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and, have no evidence of new or enlarging brain metastases and also are off steroids for 2 weeks prior to dosing with study medication.
Patients with any contraindication to receiving recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) based products.
Patients with any clinically significant autoimmune disease that requires active treatment with immunosuppressants. Replacement therapy (e.g., thyroxine, insulin) is not considered a form of systemic treatment. Short-term administration of systemic steroids (i.e., for allergic reactions, computed tomography (CT) scans, or the management of immune related adverse events [irAEs]) is allowed.
Has a known history of another prior invasive malignancy within 2 years, except subjects with early stage cancer that has undergone potentially curative therapy with no evidence of that disease recurrence for 2 years since initiation of that therapy.
Patients who are simultaneously enrolled in any other treatment study.
Patients who are pregnant or breastfeeding.
Patients with genetic driver alterations (e.g EGFR, ALK, ROS1, BRAF, MET ex 14, RET) for which targeted treatment exist and are Food and Drug Association (FDA) approved, except if the subject is not eligible or has progressed through those therapies.

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT05242965

Recruitment Status:

Not yet recruiting

Sponsor:

University of Washington

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Fred Hutch/University of Washington Cancer Consortium
Seattle Washington, 98109, United States More Info
Kris Kauno
Contact
866-932-8588
[email protected]
Laura Riolobos
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT05242965

Recruitment Status:

Not yet recruiting

Sponsor:


University of Washington

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.